Cover Image
市場調查報告書

液態切片研究工具、服務及診斷的全球市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 350412
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
液態切片研究工具、服務及診斷的全球市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日期: 2016年01月21日 內容資訊: 英文 183 Pages
簡介

全球液態切片市場預計從2015年到2020年以22.3%的年複合成長率發展,市場規模從2015年的16億美元到2020年時達到約45億美元。

本報告提供全球液態切片研究工具,服務及診斷市場相關調查,市場概要,世界市場趨勢分析,帶給液態切片技術癌症檢驗等影響,技術分析,各產品、產品類型、應用、最終用途產業、技術、適應症分析,市場動態的評估,及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 簡介
  • 調查範圍
  • 液態切片 vs. 傳統的活體組織切片
    • 市場
    • 促進成長要素
    • 主要趨勢
    • 產業

第4章 技術

  • 液態切片生物標記
  • 癌症基因學
  • 非侵襲產前檢查
  • 循環腫瘤細胞 (CTC) 技術
  • CTC工作流程
  • 細胞離析技術
  • CTC樣品製作技術
  • CTC下游分析技術
  • 液態切片和傳統活體組織切片比較
    • 癌症檢驗
    • 產前檢查

第5章 液態切片的倡議

  • 主要的協同倡議

第6章 液態切片的應用

  • 簡介
  • 癌症應用

第7章 液態切片產業

  • 簡介
  • NGS設備產業
  • 微滴式數位PCR (DDPCR) 產業
  • 靶向序列捕獲、調整產業
  • 單細胞DNA聚合酵素產業
  • 非侵襲產前檢查產業
  • 液態切片產業

第8章 收購及策略性聯盟

  • 收購
  • 策略性聯盟

第9章 市場

  • 促進成長要素
  • 液態切片市場
  • 非侵襲產前檢查市場
  • 癌症市場
  • CTC (循環腫瘤細胞) 癌症市場
  • CFDNA (無細胞DNA) 癌症市場
  • EV癌症市場
  • 移植市場
  • 液態切片市場:各地區

第10章 專利

  • CTC (循環腫瘤細胞) 專利
  • 無細胞DNA專利

第11章 企業簡介

圖表

目錄
Product Code: BIO150A

REPORT HIGHLIGHTS

The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.

This report provides:

  • An overview of the global markets for liquid biopsy research tools, services, and diagnostics
  • Analyses of global market trends, with data for 2014, estimates for 2015, and projections of CAGRs through 2020
  • Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
  • Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, research tools reagents, and more
  • Breakdowns of the market by product, product type, application, end use industry, technology, indication, as well as many others
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Profiles of major players in the industry

SCOPE AND FORMAT

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2014, 2015 and 2020.

This report reviews liquid biopsy biomarkers and technologies, and provides background on why liquid biopsy is advantageous versus tissue biopsy. It then discusses some of the top research initiatives that are contributing to liquid biopsy development. Market driving forces are also discussed.

The structure of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from 2013 to the present. Industry subsectors analyzed include NGS instruments, droplet digital PCR, target enrichment and amplification, single cell DNA polymerase, noninvasive prenatal screening and general liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. It covers commercialized diagnostic tests. The pure research field is excluded. The market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region, including North America, Europe, Asia-Pacific and the rest of the world.

Applications in this report include PCR-based, NGS-based, others (microarray, cytometry, Sanger sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC)).

Biomarker types in this report include cfDNA, CTC and EV.

Therapuetic areas in this report include cancer, NIPT and transplant.

Market data covers the years 2014, 2015 and 2020.

More than 85 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2013 through 2015, including key alliance trends.

ANALYST'S CREDENTIALS

John Bergin has written previous BCC Research biotechnology reports, including Proteomics: Technologies and Global Markets; Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomic Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds a BS in Chemistry, an MS in Biotechnology and a Masters of Business Administration.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • INTRODUCTION
    • TABLE 1: LIQUID BIOPSY SAMPLE TYPES
  • REPORT SCOPE
    • TABLE 2: LIQUID BIOPSY REPORT SCOPE
  • LIQUID BIOPSY VERSUS TRADITIONAL BIOPSY
    • MARKETS
      • TABLE 3: LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 ($ MILLIONS)
    • GROWTH DRIVING FORCES
      • TABLE 4: GROWTH DRIVING FORCES
    • KEY TRENDS
      • TABLE 5: KEY TRENDS IN LIQUID BIOPSY
    • INDUSTRY
      • TABLE 6: SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS

CHAPTER 4 - TECHNOLOGIES

  • LIQUID BIOPSY BIOMARKERS
    • TABLE 7: LIQUID BIOPSY BIOMARKER CLASSES
  • CANCER GENOMICS
    • FIGURE 1: HOW CANCER GENOMICS DRIVES LIQUID BIOPSY
    • TABLE 8: SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS
    • TABLE 9: GENOMICS-BASED ONCOLOGY WORKFLOW
  • NONINVASIVE PRENATAL TESTING
    • TABLE 10: CELL-FREE DNA ANALYSIS APPROACHES
  • CIRCULATING TUMOR CELL (CTC) TECHNOLOGIES
    • TABLE 11: UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS
  • CTC WORKFLOW
    • TABLE 12: CTC WORKFLOW
  • CELL ISOLATION TECHNOLOGIES
    • TABLE 13: CELL DIFFERENTIATORS
    • TABLE 14: CELL ISOLATION TECHNOLOGIES
  • CTC SAMPLE PREPARATION TECHNOLOGIES
    • TABLE 15: CTC SAMPLE PREPARATION TECHNOLOGIES
  • CTC DOWNSTREAM ANALYSIS TECHNOLOGIES
    • TABLE 16: SINGLE CELL ANALYSIS TECHNOLOGIES
  • COMPARISON OF LIQUID BIOPSY WITH CONVENTIONAL BIOPSY
    • CANCER TESTING
      • TABLE 17: ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR SELECTED CANCERS
      • TABLE 18: MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES
      • TABLE 19: FACTORS IN TISSUE BIOPSY
    • PRENATAL TESTING
      • TABLE 20: INVASIVE PRENATAL TESTING TECHNOLOGIES
      • TABLE 21: INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES

CHAPTER 5 - LIQUID BIOPSY INITIATIVES

  • KEY COLLABORATIVE INITIATIVES
    • TABLE 22: KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS
    • CAMBRIDGE SINGLE CELL ANALYSIS CORE FACILITY
    • CANCER-ID
    • CTC TRAP CONSORTIUM
    • EARLY CANCER DETECTION CONSORTIUM
    • HEMATOLOGIC ONCOLOGY CONSORTIUM
    • NATIONAL CENTER FOR SINGLE CELL BIOLOGY
    • PRECISION MEDICINE INITIATIVE
    • SINGLE CELL ANALYSIS PROGRAM
    • WORLDWIDE INNOVATIVE NETWORKING (WIN) CONSORTIUM

CHAPTER 6 - LIQUID BIOPSY APPLICATIONS

  • INTRODUCTION
    • TABLE 23: SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS
  • CANCER APPLICATIONS
    • PRECISION MEDICINE
      • TABLE 24: PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC MUTATIONS
    • CANCER BIOMARKER STATUS
      • TABLE 25: CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS
    • CANCER MARKET SEGMENTS
      • TABLE 26: CANCER LIQUID BIOPSY MARKET SEGMENTS
    • REPRODUCTIVE HEALTH APPLICATIONS
      • TABLE 27: NIPT AS A SCREENING APPLICATION
      • TABLE 28: ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING
    • TRANSPLANT DIAGNOSTICS APPLICATIONS
      • TABLE 29: TRANSPLANT DIAGNOSTICS APPLICATIONS

CHAPTER 7 - LIQUID BIOPSY INDUSTRY

  • INTRODUCTION
    • TABLE 30: KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY
  • NGS INSTRUMENT INDUSTRY
    • TABLE 31: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
  • DROPLET DIGITAL PCR (DDPCR) INDUSTRY
    • TABLE 32: ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS
    • TABLE 33: DDPCR INDUSTRY
  • TARGET ENRICHMENT AND AMPLIFICATION INDUSTRY
    • TABLE 34: SINGLE CELL TARGET ENRICHMENT INDUSTRY
  • SINGLE CELL DNA POLYMERASE INDUSTRY
    • TABLE 35: SINGLE CELL DNA POLYMERASE INDUSTRY
  • NONINVASIVE PRENATAL TESTING INDUSTRY
    • TABLE 36: NGS NIPT INDUSTRY
    • TABLE 37: GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS, 2015
    • TABLE 38: GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPANIES, 2015
  • LIQUID BIOPSY INDUSTRY
    • TABLE 39: LIQUID BIOPSY INDUSTRY COMPANY FOCUS

CHAPTER 8 - ACQUISITIONS AND STRATEGIC ALLIANCES

  • ACQUISITIONS
    • TABLE 40: LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015
  • STRATEGIC ALLIANCES
    • TABLE 41: SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER 2015

CHAPTER 9 - MARKETS

  • GROWTH DRIVING FORCES
    • TABLE 42: LIQUID BIOPSY MARKET GROWTH DRIVING FORCES
  • LIQUID BIOPSY MARKET
    • BY INDICATION
      • TABLE 43: LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • BY BIOMARKER TYPE
      • TABLE 44: LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 ($ MILLIONS)
    • BY ANALYSIS PLATFORM
      • TABLE 45: LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 ($ MILLIONS)
    • BY ANALYSIS PURPOSE
      • TABLE 46: LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
  • NONINVASIVE PRENATAL TESTING MARKET
    • TABLE 47: NIPT MARKET BY RISK TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 ($ MILLIONS)
  • CANCER MARKET
    • TABLE 52: CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 54: EARLY CANCER DETECTION (MM/NO.)
    • TABLE 55: CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
  • CTC CANCER MARKET
    • TABLE 57: CTC CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 58: CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
  • CFDNA CANCER MARKET
    • TABLE 59: CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 60: CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
  • EV CANCER MARKET
    • TABLE 61: EV CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
  • TRANSPLANT MARKET
    • TABLE 63: TRANSPLANT MARKET BY ORGAN TYPE, THROUGH ($ MILLIONS)
    • TABLE 64: U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER YEAR/NUMBER OF PATIENTS)
    • TABLE 65: TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 66: TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 67: TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
  • LIQUID BIOPSY MARKET BY REGION
    • TABLE 68: LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 69: CANCER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 70: NIPT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 71: TRANSPLANT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 10 - PATENTS

  • CIRCULATING TUMOR CELL PATENTS
    • TABLE 72: CTC PATENTS, 2005-2015
  • CELL-FREE DNA PATENTS
    • TABLE 73: CELL-FREE DNA PATENTS, 2005-2015

CHAPTER 11 - COMPANY PROFILES

  • AFFYMETRIX
  • AGILENT TECHNOLOGIES INC.
  • ANGLE PLC
  • ANNOROAD GENE TECHNOLOGY
  • APOCELL
  • ASURAGEN INC.
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BERRY GENOMICS CO. LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIOFLUIDICA INC.
  • BIO-RAD LABORATORIES INC.
  • BOREAL GENOMICS
  • CELL MICROSYSTEMS INC.
  • CELLSEE DIAGNOSTICS INC.
  • CELLULAR RESEARCH INC.
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CIRCULOMICS INC.
  • CLONTECH LABORATORIES INC.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOTRACK APS
  • DANAHER CORP.
  • DIAGNOLOGIX LLC
  • DNA ELECTRONICS LTD.
  • EPIC SCIENCES
  • EXOSOME DIAGNOSTICS INC.
  • FLUIDIGM CORP.
  • FOUNDATION MEDICINE
  • FLUXION BIOSCIENCES INC.
  • GATC BIOTECH AG
  • GE HEALTHCARE
  • GENOMIC HEALTH INC.
  • GIGAGEN INC.
  • GOOD START GENETICS INC.
  • GUARDANT HEALTH INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • ILLUMINA INC.
    • TABLE 74: NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015
  • JOHNSON & JOHNSON
  • KELLBENX INC.
  • LABORATORY CORP. OF AMERICA INC.
  • MDX HEALTH INC.
  • MERCK KGAA
  • MYRIAD GENETICS INC.
  • NATERA INC.
  • NEOGENOMICS INC.
  • NEW ENGLAND BIOLABS
  • NEW ONCOLOGY AG
  • NUGEN TECHNOLOGIES INC.
  • OXFORD GENE TECHNOLOGY
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PATHWAY GENOMICS CORP.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • RAINDANCE TECHNOLOGIES INC.
  • RARECELLS SAS
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
    • TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING
  • RUBICON GENOMICS
  • SALVEO DX
  • SCREENCELL
  • SENGENICS INTERNATIONAL PTE LTD.
  • SEQUENOM INC.
  • SILICON BIOSYSTEMS
  • SPHERE FLUIDICS LTD.
  • STRAND LIFE SCIENCES
  • STRATEC BIOMEDICAL AG
  • SYGNIS AG
  • SYSMEX INOSTICS
  • TAI DIAGNOSTICS INC.
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TROVAGENE INC.
  • TRANSGENOMIC INC.
  • VITATEX INC.
  • WAFERGEN BIO-SYSTEMS INC.
    • TABLE 76: WAFERGEN STRATEGIC ALLIANCES
  • XCELL BIOSCIENCES INC.
  • YIKON GENOMICS CO. LTD.
  • ZEPHYRUS BIOSCIENCES INC.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: LIQUID BIOPSY SAMPLE TYPES
    • TABLE 2: LIQUID BIOPSY REPORT SCOPE
    • TABLE 3: LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 4: GROWTH DRIVING FORCES
    • TABLE 5: KEY TRENDS IN LIQUID BIOPSY
    • TABLE 6: SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS
    • TABLE 7: LIQUID BIOPSY BIOMARKER CLASSES
    • TABLE 8: SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS
    • TABLE 9: GENOMICS-BASED ONCOLOGY WORKFLOW
    • TABLE 10: CELL-FREE DNA ANALYSIS APPROACHES
    • TABLE 11: UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS
    • TABLE 12: CTC WORKFLOW
    • TABLE 13: CELL DIFFERENTIATORS
    • TABLE 14: CELL ISOLATION TECHNOLOGIES
    • TABLE 15: CTC SAMPLE PREPARATION TECHNOLOGIES
    • TABLE 16: SINGLE CELL ANALYSIS TECHNOLOGIES
    • TABLE 17: ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR SELECTED CANCERS
    • TABLE 18: MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES
    • TABLE 19: FACTORS IN TISSUE BIOPSY
    • TABLE 20: INVASIVE PRENATAL TESTING TECHNOLOGIES
    • TABLE 21: INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES
    • TABLE 22: KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS
    • TABLE 23: SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS
    • TABLE 24: PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC MUTATIONS
    • TABLE 25: CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS
    • TABLE 26: CANCER LIQUID BIOPSY MARKET SEGMENTS
    • TABLE 27: NIPT AS A SCREENING APPLICATION
    • TABLE 28: ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING
    • TABLE 29: TRANSPLANT DIAGNOSTICS APPLICATIONS
    • TABLE 30: KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY
    • TABLE 31: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
    • TABLE 32: ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS
    • TABLE 33: DDPCR INDUSTRY
    • TABLE 34: SINGLE CELL TARGET ENRICHMENT INDUSTRY
    • TABLE 35: SINGLE CELL DNA POLYMERASE INDUSTRY
    • TABLE 36: NGS NIPT INDUSTRY
    • TABLE 37: GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS, 2015
    • TABLE 38: GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPANIES, 2015
    • TABLE 39: LIQUID BIOPSY INDUSTRY COMPANY FOCUS
    • TABLE 40: LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015
    • TABLE 41: SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER 2015
    • TABLE 42: LIQUID BIOPSY MARKET GROWTH DRIVING FORCES
    • TABLE 43: LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 44: LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: NIPT MARKET BY RISK TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 54: EARLY CANCER DETECTION (MM/NO.)
    • TABLE 55: CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 57: CTC CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 58: CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 60: CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: EV CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 63: TRANSPLANT MARKET BY ORGAN TYPE, THROUGH ($ MILLIONS)
    • TABLE 64: U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER YEAR/NUMBER OF PATIENTS)
    • TABLE 65: TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 66: TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 67: TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
    • TABLE 68: LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 69: CANCER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 70: NIPT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 71: TRANSPLANT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 72: CTC PATENTS, 2005-2015
    • TABLE 73: CELL-FREE DNA PATENTS, 2005-2015
    • TABLE 74: NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015
    • TABLE 75: COMMERCIAL SEQUENCER COMPETITIVE POSITIONING
    • TABLE 76: WAFERGEN STRATEGIC ALLIANCES

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)
    • FIGURE 1: HOW CANCER GENOMICS DRIVES LIQUID BIOPSY
Back to Top